REFERENCES
1. Clinical recommendations. Chlamydial infection. Ministerstvo zdravookhraneniya RF, 2021. ID: KP194. (in Russian)
2. Clinical recommendations. The urogenital diseases caused by Mycoplasma genitalium. Ministerstvo zdravookhraneniya RF, 2021. ID: KP216. (in Russian)
3. Clinical recommendations about diagnostics and treatment of the diseases which are followed by pathological allocations from a genital tract of women. 2nd ed., correct. and suppl. Moscow: ROAG, 2019. (in Russian)
4. Federal clinical recommendations. Dermatovenereology of 2015: Skin diseases. Infections, sexually transmitted. 5th ed., correct. and suppl. Moscow: Delovoy ekspress, 2016: 768 p. (in Russian)
5. Felix T.C., de Brito Röder D.V.D., Dos Santos Pedroso R. Alternative and complementary therapy for vulvovaginal candidiasis. Folia Microbiol. 2019; 64 (2): 133–41.
6. Goswami R., Dadhwal V., Tejasvi S., et al. The species – specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect. 2000; 41 (2): 162–6.
7. Goswami D., Goswami R., Banerjee U., et al. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. J Infect. 2006; 52 (2): 111–7.
8. de Leon E.M., Jacober S.J., Sobel J.D., Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis. 2002; 2: 1.
9. Mycology today. Vol. 1. In: Yu.T. Dyakov, Yu.V. Sergeev (eds). Moscow: Natsional’naya academiya mykologii, 2007: 376 p. (in Russian)
10. Nyman G.S.A., Tang M., Inerot A., Osmancevic A., Malmberg P., Hagvall L. Contact allergy to beeswax and propolis among patients with cheilitis or facial dermatitis. Contact Dermatitis. 2019; 81 (2): 110–6.
11. De Bernardis F., Boccanera M., Cassone A. The role of humoral immunity in relation to vaginal candida infection. In: Fungal Immunology. Springer, 2005: 345– 55.
12. Mirzabalaeva A.K., Klimko N.N. Diagnosis and treatment of genital candidiasis in women, girls and adolescents Saint Petersburg: SPbMAPO, 2009: 60 p. (in Russian)
13. van de Wijgert J., Verweijs M.C., Turner A.N., Morrison C.S. Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission. AIDS. 2013; 27: 2141–53.
14. Zhao X., Malloy P.J., Ardies C.M., Feldman D. Oestrogen-binding protein in Candida albicans: antibody development and cellular localization by electron immunocytochemistry. Microbiology. 1995; 141 (Pt 10): 2685–92.
15. Pericolini E., Perito S., Castagnoli A., et al. Epitope unmasking in vulvovaginal candidiasis is associated with hyphal growth and neutrophilic infiltration. PLoS One. 2018; 13 (7): e0201436.
16. Muzny C.A., Schwebke J.R. Biofilms: an underappreciated mechanism of treatment failure and recurrence in vaginal infections. Clin Infect Dis. 2015; 61 (4): 601–6.
17. Dennerstein G.J., Ellis D.H. Oestrogen, glycogen and vaginal candidiasis. Aust N Z J Obstet Gynaecol. 2001; 41 (3): 326–8.
18. Yano J., Peters B.M., Noverr M.C., Fidel P.L. Jr. Novel mechanism behind the immunopathogenesis of vulvovaginal candidiasis: «Neutrophil Anergy». Infect Immun. 2018; 86 (3): e00684-17. DOI: https://doi.org/10.1128/IAI.00684-17
19. Willems H.M.E., Ahmed S.S., Liu J., Xu Z., Peters B.M. Vulvovaginal candidiasis: a current understanding and burning questions. J Fungi (Basel). 2020; 6 (1): 27.
20. Naglik J.R., Gaffen S.L., Hube B. Candidalysin: discovery and function in Candida albicans infections. Curr Opin Microbiol. 2019; 52: 100–9.
21. Kalo-Klein A., Witkin S.S. Candida albicans: cellular immune system interactions during different stages of the menstrual cycle. Am J Obstet Gynecol. 1989; 161 (5): 1132–6.
22. Fidel P.L. Jr. Immunity in vaginal candidiasis. Curr Opin Infect Dis. 2005; 18 (2): 107–11.
23. Ho J., Wickramasinghe D.N., Nikou S.A., Hube B., Richardson J.P., Naglik J.R. Candidalysin is a potent trigger of alarmin and antimicrobial peptide release in epithelial cells. Cells. 2020; 9 (3): 699. DOI: https://doi.org/10.3390/cells9030699
24. Sergeev A.Yu., Sergeev Yu.V. Candidiasis. The nature of infection, mechanisms of aggression and defense, laboratory diagnostics, clinic and treatment. Moscow, 2001: 472 p (in Russian)
25. Walker P.P., Reynolds M.T., Ashbee H.R., Brown C., Evans E.G. Vaginal yeasts in the era of «over the counter» antifungals. Sex Transm Infect. 2000; 76 (6): 437–8.
26. Ferris D.G., Nyirjesy P., Sobel J.D., Soper D., Pavletic A., Litaker M.S. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol. 2002; 99 (3): 419–25.
27. Gobernado M., et al. Bacterial identification methods. Enferm Infecc Microbiol Clin. 2003; 21 (2): 6–13.
28. Hoffstetter S.E., Barr S., Lefevre K., Leong F.K., Leet T. Self-reported yeast symptoms compared with clinical wet mount analysis and vaginal yeast culture in a specialty clinic setting. J Reprod Med. 2008; 53 (6): 402–6.
29. Plempel M. Pharmacokinetics of imidazole-antimycotics. Mycosen. 1980; 23 (1): 16–27.
30. Shcheklakov N.D., Delektorsky V.V., Golodova O.A. Ultrastructural changes in Candida albicans caused by polyene antibiotics. Mycosen. 1981; 24 (3): 140–52.
31. Gerasimova N.M., Bodumyan T.M. Terbinafin (lamizil) in the treatment of fungal skin diseases: topical issues of our time. Vestnik dermatologii and venerologii [Bulletin of Dermatology and Venereology]. 2006; (6): 34–7. (in Russian)
32. Nivert M., Kunze D., Seibold M., Schaller M., Corting H.K., Hube B. Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins and drug resistance factors. Antimicrob Agents Chemother. 2003; 47 (6): 1805–17.
33. Savicheva A.M., Kisina V.I., Sokolovsky E.V., et al. Candida vulvovaginitis. Guidelines for physicians. Saint Petersburg: Izdatel’srvo N-L, 2009: 88 p. (in Russian)
34. Kere K., Zhelya B., Chevalier T., Petit F., Micheletti M.K. Evaluation of the effectiveness and rate of action of sertaconazole nitrate and cream suppositories in the combined treatment of vulvovaginal candidiasis. Gynecol Obstet Fertil. 2000; 28 (3): 238–44.
35. Mendling V., Schlegelmilch R. Three-day combined treatment of vulvovaginal candidiasis with vaginal suppositories of 200 mg clotrimazole and clotrimazole cream for the vulva is significantly better than treatment with vaginal suppositories alone – an earlier multicenter placebo-controlled double-blind study. Geburtshilfe Frauenheilkd. 2014; 74 (4): 355–60.
36. Donders G.G., Sobel D.D. Candida vulvovaginitis: a store with a buttery and a show window. Mycoses. 2017; 60 (2): 70–2.
37. Das Neves J., Pinto E., Teixeira B., et al. Local treatment of vulvovaginal candidiasis: general and practical considerations. Drugs. 2008; 68 (13): 1787–802.
38. Sychev D.A., Otdelenov V.A., Denisenko N.P., Smirnov V.V. The study of the activity of cytochrome isoenzymes R450 to predict drug-drug interactions in polypharmacy. Farmakogenetika i farmakogenomika [Pharmacogenetics and Pharmacogenomics]. 2016; (2): 4–11. (in Russian)
39. Richter S.S., Galask R.P., Messer S.A., Hollis R.J., Dikema D.J., Pfaller M.A. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005; 43 (5): 2155–62.
40. Talaei Z., Sheikhbahaei S., Ostadi V., et al. Recurrent vulvovaginal candidiasis: could it be related to cell-mediated immunity defect in response to Candida antigen? Int J Fertil Steril. 2017; 11 (3): 134–41.
41. Fadiel A., Lee H.H., Demir N., Richman S., Iwasaki A., Connell K., Naftolin F. Ezrin is a key element in the human vagina. Maturitas. 2008; 60 (1): 31–41.
42. Pore D., Gupta N. The ezrin-radixin-moesin family of proteins in the regulation of B-cell immune response. Crit Rev Immunol. 2015; 35 (1): 15–31.
43. De Bernardis F., Arancia S., Sandini S., Graziani S., Norelli S. Studies of immune responses in Candida vaginitis. Pathogens. 2015; 4 (4): 697–707.
44. Holms R.D., Bessler W.G., Konopleva M.V., Ataullakhanov R.I. Review of Russian ezrin peptide treatment of acute viral respiratory disease and virus induced pneumonia; a potential treatment for COVID-19. 2020.
45. Novokshonov A.A., Sokolova N.V., Galeeva E.V., Kurbanova G.M., Portnykh O.Yu., Uchaykin V.F. Immunotherapy for acute intestinal infections in children. Experience in the use of a new immunomodulator «Gepon». Detskie infektsii [Children’s Infections]. 2003; (1): 32–6. (in Russian)
46. Parfenov A.I., Ruchkina I.N., Ataullakhanov R.I. Local immunity activator Gepon in the complex therapy of dysbiotic disorders of the intestine. Eksperimental’naya i klinicheskaya gastoenterologiya [Experimental and Clinical Gastroenterology]. 2003; (3): 66–9. (in Russian)
47. Tishchenko A.L. A new approach to the treatment of recurrent urogenital candidiasis. Ginekologiya [Gynecology]. 2001; 3 (6): 210–2. (in Russian)
48. Shabashova N.V., Kuz’mina D.A., Frolova E.V., Simbarskaya M.L., Uchevatkina A.E., Filippova L.V., et al. Violations of local immunity and immunotherapy with Gepon in chronic inflammation of the mucous membranes of different localization. Vestnik Sankt-Peterburgskoy meditsinskoy akademii poslediplomnogo obrazovaniya [Bulletin of the Saint Petersburg Medical Academy of Postgraduate education]. 2010; 2 (4): 59–64. (in Russian)
49. Khaitov R.M., Ataullakhanov R.I., Shul’zhenko A.E. (eds). Immunotherapy. A guide for physicians. 2nd ed. Moscow: GEOTAR-Media, 2020: 768 p. (in Russian)
50. Telunets A.V. Treatment of candidiasis in young children. Voprosy ginekologii, akusherstva i perinatologii [Problems of Gynecology, Obstetrics and Perinatology]. 2004; 3 (4): 89–90. (in Russian)